What happened with BBOT today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
BridgeBio Oncology Therapeutics is developing oral drugs for cancers driven by RAS and PI3Kα signaling, which helps cancer cells grow. Its internally designed candidates either inhibit KRAS directly or block the interaction between RAS and PI3Kα. BBO-8520, BBO-11818 and BBO-10203 are in Phase 1 clinical trials; the company has not completed a clinical trial and has no approved products or revenue.
Investors, rather than drug customers, currently supply its funding, primarily through equity sales. If its candidates receive approval, the company plans to sell them itself or with a commercial partner. Future sales would depend on successful clinical development, regulatory approval and insurers’ and other payors’ coverage and reimbursement. It cannot market or promote its candidates before approval and needs additional capital to complete development and commercialization.
The company outsources manufacturing and relies on exclusive patent licenses from Lawrence Livermore National Security, LLC and Leidos Biomedical Research, Inc. These licenses require development progress and payments, including royalties on future sales; failure to meet their terms can cost the company its licensed rights or exclusivity.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
BBOT depends on clinical results and continued funding, with Roche’s KRAS and PI3Kα drugs key competition and Lawrence Livermore National Security supplying foundational intellectual-property licenses.
Revolution Medicines is developing drugs that block active RAS in G12C, G12D and G12V cancers, directly overlapping BBOT’s KRAS drug programs. Watch elironrasib’s clinical results against the opportunity for BBO-8520 in KRAS G12C non-small-cell lung cancer.
Erasca’s drugs targeting multiple KRAS or RAS variants compete with BBOT’s BBO-11818 for KRAS-mutant solid tumors. Clinical results for ERAS-4001 and ERAS-0015 will help frame that competition; ERAS-4001’s reported activity in G12D and G12V tumors is still preclinical.
Adlai Nortye’s AN9025, an oral drug blocking multiple active RAS variants, competes with BBOT’s BBO-11818 for RAS-driven solid tumors. Watch its Phase I results: Adlai Nortye’s claims of stronger activity than a clinical benchmark come from laboratory and animal models, not patient results.
BlossomHill Therapeutics’ BH-501284 targets multiple KRAS variants and the same cancer-treatment opportunity as BBOT’s BBO-11818. BH-501284 remains preclinical, so its progress toward patient trials is the development to watch rather than drug sales.
Amgen already markets LUMAKRAS (sotorasib) for KRAS G12C lung cancer, giving BBOT’s BBO-8520 an approved treatment to compete against if it wins approval. Amgen earns revenue selling medicines through wholesalers and healthcare providers; LUMAKRAS is the product relevant to BBOT, rather than Amgen’s overall sales.
Bristol Myers Squibb sells KRAZATI (adagrasib), an approved KRAS G12C treatment that BBOT’s BBO-8520 would compete against in lung cancer if approved. News about adagrasib is therefore more relevant to this BBOT program than Bristol Myers Squibb’s broader medicines business.
Eli Lilly competes with two BBOT programs: olomorasib overlaps BBO-8520 in KRAS G12C lung cancer, while STX-478 overlaps BBO-10203 in PI3Kα-driven breast cancer.
AstraZeneca’s capivasertib competes in the hormone receptor-positive breast-cancer setting targeted by BBOT’s BBO-10203, making this drug the relevant overlap to watch.
Elicio Therapeutics and BBOT both depend on progress in treating KRAS-mutant pancreatic and colorectal cancers, but Elicio develops cancer vaccines while BBOT develops KRAS-blocking drugs. Elicio’s Phase 2 ELI-002 7P results in pancreatic ductal adenocarcinoma offer a view of progress in that patient group, not a direct test of BBO-11818.
Revolution Medicines, Inc. earningsRVMD
Revolution Medicines’ report will show how its KRAS drugs are progressing in clinical development, including the lung-cancer setting where its programs overlap with BridgeBio Oncology Therapeutics’ BBO-8520.
Watch for any clinical results for elironrasib in KRAS G12C lung cancer. Evidence of activity would show a competitor making progress in the patient group targeted by BBO-8520 and could raise the bar for BBOT to demonstrate its drug’s value; limited progress would suggest less competitive pressure, but would not prove BBO-8520 works. The takeaway is how far the competing program has advanced, not a result for BBOT’s own drug.
BridgeBio Oncology Therapeutics, Inc. earningsThis company
BridgeBio Oncology Therapeutics has no product revenue, so its report will show how quickly it uses cash to advance its three cancer-drug programs.
Read cash used in operating activities alongside R&D spending, then compare both with any reported progress in the clinical programs. Slower cash use with continued progress would mean the available funds can support development for longer; faster cash use without corresponding progress would raise pressure to seek funding or slow programs. The question is whether spending is advancing the candidates and how long the funding can support that work.
